HOME >> MEDICINE >> NEWS
New therapeutic target identified in inherited brain tumor disorder

St. Louis, Nov. 1, 2005 -- Researchers studying a mouse model of neurofibromatosis 1 (NF1), a genetic condition that causes childhood brain tumors, have found their second new drug target in a year, a protein called methionine aminopeptidase-2 (MetAP2).

An established drug, fumagillin, is already known to suppress the activity of MetAP2. Researchers at Washington University School of Medicine in St. Louis showed that fumagillin significantly slowed the rapid proliferation of cultured mouse brain cells that resulted from the loss of Nf1, the gene that causes neurofibromatosis 1. Evaluation of the ability of this class of drugs to control brain tumor growth in small animal models is planned.

"This agent and others like it have already been in clinical trials as treatments for other tumors, so if we find that fumagillin inhibits brain tumor growth in preclinical studies, it will be a much smaller leap to using these compounds in patients with NF1," says senior investigator David H. Gutmann, M.D., Ph.D., the Donald O. Schnuck Family Professor of Neurology at Washington University School of Medicine in St. Louis and co-director of the neuro-oncology program at the Siteman Cancer Center.

Neurofibromatosis 1 affects more than 100,000 people in the United States and is one of the most common tumor predisposition syndromes. Gutmann and his colleagues discovered that abnormally high levels of MetAP2 may be a distinguishing characteristic of brain tumors in patients with NF1. Analyses of other similar brain tumors did not reveal the high MetAP2 levels characteristic of tumors caused by NF1.

To identify MetAP2, Gutmann collaborated with Jason D. Weber, Ph.D., assistant professor of medicine and of cellular biology and anatomy at the Washington University Neurofibromatosis Center. The center facilitates multidisciplinary neurofibromatosis research and is dedicated to developing better treatments to improve the lives of patients affected with neurofibromat
'"/>

Contact: Michael C. Purdy
purdym@wustl.edu
314-286-0122
Washington University School of Medicine
1-Nov-2005


Page: 1 2

Related medicine news :

1. Shark cartilage shows no benefit as a therapeutic agent for lung cancer
2. New therapeutic targets for neurodegenerative diseases
3. OCT1 required for therapeutic effects of diabetes drug Metformin
4. NeuroRx changes name to Neurotherapeutics
5. Olive Leaf report documents promising therapeutic interventions for 9-11 workers
6. T cells activated to fight HIV basis for dendritic cell therapeutic vaccine
7. Cerebrospinal fluid used to deliver therapeutics for Lou Gehrigs disease to brain
8. University to develop new therapeutics for cancer
9. Exubera: So far no evidence available of an additional therapeutic benefit
10. Nano-particles effective in killing cancer with one-two punch of chemotherapeutics
11. Researchers identify target for therapeutic drugs to fight most common adult brain cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/1/2020)... ... September 01, 2020 , ... ... specialty fellowship training in aesthetic surgery of the face, breast, and body. In ... only female-owned premier boutique plastic surgery and aesthetic practice in Southwest Florida. Dr. ...
(Date:8/31/2020)... NEW YORK (PRWEB) , ... August 31, 2020 ... ... the nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and ... and patient services – today announced the 10th Anniversary of Blood Cancer Awareness ...
(Date:8/31/2020)... ... August 31, 2020 , ... Ocean Springs, ... masks to medical first responders across the United States. Since the start of ... protective equipment (PPE) medical centers , hospitals , firefighters , ...
(Date:8/31/2020)... ... 31, 2020 , ... Genesis Chiropractic Software and Billing ... launch of its integrated, HIPAA compliant, telehealth solution, available to US-based clients immediately. ... 90 seconds. , According to the U.S. Department of Health & Human ...
(Date:8/31/2020)... IRVINE, Calif. (PRWEB) , ... August 31, 2020 ... ... providers of business support services to dental groups in the United States, today ... serving the community of Beaumont, CA. , Patients will enjoy convenient hours, ...
Breaking Medicine News(10 mins):
(Date:8/27/2020)... ... August 27, 2020 , ... Trella Health, the leading source ... of cloud CRM, marketing automation, and contact center solutions for senior living communities ... of Trella’s performance intelligence data and insights into Enquire’s CRM solution to serve ...
(Date:8/26/2020)... ... August 26, 2020 , ... ... Laboratory Testing division, expands its technology footprint with the addition of Novocyte ... available. With industry-leading biomarker solutions, complemented with traditional ligand-binding assays and study ...
(Date:8/26/2020)... ... ... Hero Life Sciences announced today that it will be setting up ... masks and N95 respirators in its manufacturing plant located in the City of Corona, ... facing in trying to find quality disposable face masks during the COVID-19 pandemic and ...
Breaking Medicine Technology:
Cached News: